Table 3.
Compliance and persistence with lipid-modifying therapy
| Outcome measure by therapy | First event | Second event | |||
| Prior history of vascular disease | Prior history of diabetes | Prior history of vascular disease + diabetes | Other high risk | ||
| Statin (N) | 7380 | 2807 | 2773 | 5470 | 3725 |
| Compliance (mean (SD)) | 0.79 (0.33) | 0.76 (0.35) | 0.79 (0.33) | 0.76 (0.35) | 0.79 (0.32) |
| Adherence (N (%)) | 5261 (71.3) | 1905 (67.9) | 1990 (71.8) | 3748 (68.5) | 2671 (71.7) |
| Treatment duration (mean (SD)) | 237.57 (142.08) | 202.28 (149.14) | 228.87 (144.83) | 210.56 (148.38) | 215.76 (144.89) |
| Persistence (N (%)) | 3747 (50.8) | 1413 (50.3) | 1415 (51.0) | 2807 (51.3) | 1947 (52.3) |
| Ezetimibe (N) | 258 | 101 | 120 | 161 | 148 |
| Compliance (mean (SD)) | 0.77 (0.35) | 0.77 (0.34) | 0.74 (0.36) | 0.72 (0.37) | 0.79 (0.32) |
| Adherence (N (%)) | 179 (69.4) | 70 (69.3) | 78 (65.0) | 104 (64.6) | 104 (70.3) |
| Treatment duration (mean (SD)) | 235.83 (143.81) | 206.86 (147.95) | 207.23 (146.65) | 208.23 (154.10) | 239.56 (134.94) |
| Persistence (N (%)) | 120 (46.5) | 39 (38.6) | 56 (46.7) | 67 (41.6) | 74 (50.0) |
| Fibrate (N) | 78 | 51 | 47 | 94 | 55 |
| Compliance (mean (SD)) | 0.69 (0.39) | 0.65 (0.40) | 0.72 (0.32) | 0.58 (0.42) | 0.73 (0.35) |
| Adherence (N (%)) | 46 (59.0) | 29 (56.9) | 26 (55.3) | 45 (47.9) | 34 (61.8) |
| Treatment duration (mean (SD)) | 201.09 (148.83) | 170.76 (144.28) | 216.87 (138.19) | 160.75 (149.41) | 206.75 (147.16) |
| Persistence (N (%)) | 36 (46.2) | 17 (33.3) | 17 (36.2) | 32 (34.0) | 25 (45.5) |
See methods for definitions of outcome measures. Individuals receiving statins with ezetimibe were classified as statin users.